# eAppendix 1: Individual disease courses

Individual disease course of each person with limbic encephalitis, categorized by underlying antibody: glutamic acid decarboxylase 65 (GAD), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2) and N-methyl-D-aspartate-receptor (NMDAR). We only included subjects with two or more timepoints of MRI into this overview.

- Left Hippocampus
- Right Hippocampus
- Left Amygdala
- Right Amygdala
- Pulse steroid therapy
- Oral immuno-suppressants
- IVIG / plasmapheresis
- Verbal memory
- Figural memory
- Verbal memory
- Figural memory

Blue area in the background represents number of anti-seizure medication prescribed
IVIG: Intravenous immunoglobulin

# People with glutamic acid decarboxylase 65 (GAD) antibodies

Subject: **3** Group: **GAD**, Age at Onset: **18**, Affected: **left**

Subject: **4** Group: **GAD**, Age at Onset: **19**, Affected: **left**

Subject: **5** Group: **GAD**, Age at Onset: **16**, Affected: **left**


## Subject: **7** Group: **GAD**, Age at Onset: **44**, Affected: **left**

Subject: **8** Group: **GAD**, Age at Onset: **28**, Affected: **left**

Subject: **10** Group: **GAD**, Age at Onset: **21**, Affected: **left**

## Subject: **11** Group: **GAD**, Age at Onset: **13**, Affected: **right**

## Subject: **14** Group: **GAD**, Age at Onset: **28**, Affected: **left**

Subject: **16** Group: **GAD**, Age at Onset: **42**, Affected: **left**


Subject: **17** Group: **GAD**, Age at Onset: **25**, Affected: **left**

Subject: **19** Group: **GAD**, Age at Onset: **27**, Affected: **left**

Subject: **22** Group: **GAD**, Age at Onset: **18**, Affected: **left**

Subject: **23** Group: **GAD**, Age at Onset: **21**, Affected: **left**

Subject: **25** Group: **GAD**, Age at Onset: **48**, Affected: **left**

Subject: **26** Group: **GAD**, Age at Onset: **42**, Affected: **left**

Subject: **32** Group: **GAD**, Age at Onset: **24**, Affected: **left**

Subject: **34** Group: **GAD**, Age at Onset: **18**, Affected: **right**

Subject: **36** Group: **GAD**, Age at Onset: **21**, Affected: **right**

Subject: 37 Group: GAD, Age at Onset: 30, Affected: right

**Subject: 38 Group: GAD, Age at Onset: 26, Affected: right**

Subject: **39** Group: **GAD**, Age at Onset: **19**, Affected: **left**

Subject: **40** Group: **GAD**, Age at Onset: **16**, Affected: **left**

Subject: **41** Group: **GAD**, Age at Onset: **46**, Affected: **left**

# Poeple with leucine-rich glioma-inactivated 1 (LGI1) antibodies

Subject: **1** Group: **LGI1**, Age at Onset: **69**, Affected: **left**


Subject: **2** Group: **LGI1**, Age at Onset: **54**, Affected: **right**

Subject: **6** Group: **LGI1**, Age at Onset: **73**, Affected: **left**

Subject: **9** Group: **LGI1**, Age at Onset: **75**, Affected: **left**

Subject: **12** Group: **LGl1**, Age at Onset: **62**, Affected: **right**

Subject: **15** Group: **LGl1**, Age at Onset: **64**, Affected: **left**

## Subject: **21** Group: **LGI1**, Age at Onset: **89**, Affected: **right**

Subject: **24** Group: **LGI1**, Age at Onset: **91**, Affected: **left**

Subject: **28** Group: **LGI1**, Age at Onset: **48**, Affected: **right**

Subject: **31** Group: **LGI1**, Age at Onset: **61**, Affected: **left**

Subject: **43** Group: **LGI1**, Age at Onset: **59**, Affected: **left**

**People with contactin-associated protein-like 2 (CASPR2) antibodies**

Subject: **13** Group: **CASPR2**, Age at Onset: **41**, Affected: **left**

Subject: **18** Group: **CASPR2**, Age at Onset: **48**, Affected: **left**

Subject: **20** Group: **CASPR2**, Age at Onset: **57**, Affected: **left**

Subject: **29** Group: **CASPR2**, Age at Onset: **68**, Affected: **left**

Subject: **33** Group: **CASPR2**, Age at Onset: **37**, Affected: **left**

Subject: **35** Group: **CASPR2**, Age at Onset: **69**, Affected: **left**

People with N-methyl-D-aspartate-receptor (NMDAR) antibodies

Subject: **30** Group: **NMDAR**, Age at Onset: **43**, Affected: **left**

Subject: **27** Group: **NMDAR**, Age at Onset: **25**, Affected: **left**

Subject: **42** Group: **NMDAR**, Age at Onset: **66**, Affected: **right**